Clinical Trial Update: A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis [Phase 4]

View source ↗

Summary

A Phase 4 randomized trial evaluating IV ketorolac to prevent post-ERCP pancreatitis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatitis

Drugs mentioned

• Ketorolac (Ketorolac tromethamine)

Snippet

Sponsor: University of California, San Francisco | Conditions: Pancreatitis | Phase 4 | Status: WITHDRAWN